skin cancer
Castle Biosciences Q4 Revenues up 31 Percent
The company saw a boost in testing volume in the fourth quarter, but not across all its assays, while full-year revenues grew 51 percent.
Akoya Biosciences Licenses Early-Stage Melanoma Test From NeraCare
The exclusive license agreement builds on an existing research collaboration between the companies to develop assays for skin cancer using Akoya's immunofluorescence platform.
ASHG: Herpesvirus Integrated in Human Genome Increases Skin Cancer Risk, UK Biobank Study Finds
Premium
Researchers showed that inherited chromosomally integrated HHV-6 (ici-HHV-6) is associated with a threefold increase in basal cell carcinoma risk.
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.
Aug 5, 2024
Castle Biosciences Q2 Revenues Jump 74 Percent
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
May 4, 2022